Introduction
============

The optimal duration of antibiotic treatment in critically ill patients remains a subject of debate. In our multidisciplinary ICU, a short course of antibiotic monotherapy (5 to 7 days) is generally used as a strategy to treat bacteraemia, unless specifically indicated otherwise (for example, endocarditis, osteomyelitis). We aimed to determine the impact of this strategy on antibiotic resistance patterns and patient outcomes compared with a similar exercise we conducted in 2000 \[[@B1]\].

Methods
=======

We conducted a retrospective study of all patients with bacteraemia or fungaemia (community-acquired, hospital-acquired, and ICU-acquired) treated in our university hospital ICU over a 6-month period (December 2012 to May 2013). We compared this against data from blood culture-positive patients admitted between February and July 2000. Information was collected on bacteraemia episodes, causative pathogens, antimicrobial resistance patterns, antibiotic use and duration, and patient outcomes. Notably, our ICU admits many immunosuppressed patients (for example, haemoncology).

Results
=======

Table [1](#T1){ref-type="table"} presents demographics and incidence of bacteraemia. Antimicrobial resistance remained low in the 2013 cohort with few multi-resistant Gram-negative organisms, few fungaemia episodes and a marked decrease in methicillin-resistant *Staphylococcus aureus*(MRSA) (Figure [1](#F1){ref-type="fig"}). The number of relapses and breakthrough bacteraemias remained low.

###### 

Demographics and incidence of bacteraemia

  Variable                                           2000 cohort       2013 cohort
  -------------------------------------------------- ----------------- -----------------
  Total ICU population                               713               1,318
  Patients with bacteraemia                          91                87
  Episodes of bacteraemia                            102               113
     Community-acquired bacteraemia                  13                37
     Hospital-acquired bacteraemia                   28                39
     ICU-acquired bacteraemia                        60                37
  Hospital mortality                                 45%               32%
  Monotherapy treatment (%); duration median (IQR)                      
     Community-acquired bacteraemia                  57%; 6 (5 to 6)   65% 5 (3 to 5;
     Hospital-acquired bacteraemia                   78%; 6 (5 to 8)   63%; 5 (4 to 7)
     ICU-acquired bacteraemia                        80%; 5 (5 to 7)   62%; 4 (3 to 6)

![**Microorganisms isolated in each bacteraemia group**. Left panel, 2000; right panel, 2013. Top panel, community-acquired bacteraemia; Middle panel, hospital-acquired bacteraemia; lower panel, ICU-acquired bacteraemia. Shaded areas represent numbers of methicillin-resistant strains for S. aureus and coagulase-negative staphylococci; vancomycin-resistant strains for Enterococcus spp.; multidrug-resistant strains for Gram-negative pathogens; and fluconazole-resistant strains for Candida spp.](cc13547-1){#F1}

Conclusion
==========

A strategy of short-course antibiotic monotherapy is associated with low breakthrough and relapse rates and a low rate of antibiotic resistance.
